PRVB insider filings
Provention Bio, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-04-28. Screen PRVB transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PRVB between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Provention Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-04-28 | 4 | Sessa Capital (Master), L.P. — 10% owner Sessa Capital GP, LLC — 10% owner Sessa Capital IM, L.P. — 10% owner Sessa Capital IM GP, LLC — 10% owner Petry John — 10% owner | Code (U): 15,567,497 | EDGAR |
| 2023-04-27 | 4 | Pisano Wayne — Director | Code (U): 7,500 · Disposition to issuer (D): 128,981 (derivative) · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 22,200 (derivative) · Disposition to issuer (D): 23,000 (derivative) · Disposition to issuer (D): 33,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Jenkins John Kenneth — Director | Disposition to issuer (D): 128,981 (derivative) · Disposition to issuer (D): 23,000 (derivative) · Disposition to issuer (D): 33,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Jain Rita — Director | Disposition to issuer (D): 66,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Yi Miyoko Christina — Chief Operations Officer | Disposition to issuer (D): 300,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 187,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Leon Francisco — Chief Scientific Officer | Code (U): 73,000 · Code (U): 1,500,000 · Code (U): 1,000,000 · Disposition to issuer (D): 242,103 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 137,750 (derivative) · +3 more | EDGAR |
| 2023-04-27 | 4 | Osorio Benedict — Chief Quality Officer | Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 187,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Hoitt Jason — Chief Commercial Officer | Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 137,750 (derivative) · Disposition to issuer (D): 139,500 (derivative) · Disposition to issuer (D): 145,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | King-Jones Heidy — Chief Legal Officer | Disposition to issuer (D): 300,000 (derivative) · Disposition to issuer (D): 139,500 (derivative) · Disposition to issuer (D): 145,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Chauche Thierry — Chief Financial Officer | Disposition to issuer (D): 375,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Vogel Justin — Chief Accounting Officer | Disposition to issuer (D): 88,185 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 66,000 (derivative) · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 84,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | Palmer Ashleigh — Director and CEO | Code (U): 2,570,050 · Disposition to issuer (D): 441,720 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 137,750 (derivative) · Disposition to issuer (D): 139,500 (derivative) · Disposition to issuer (D): 360,000 (derivative) · +1 more | EDGAR |
| 2023-04-27 | 4 | Ramos Eleanor — Chief Medical Officer | Code (U): 70,000 · Disposition to issuer (D): 460,462 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 137,750 (derivative) · Disposition to issuer (D): 139,500 (derivative) · Disposition to issuer (D): 145,000 (derivative) · +1 more | EDGAR |
| 2023-04-27 | 4 | Wysenski Nancy — Director | Disposition to issuer (D): 128,981 (derivative) · Disposition to issuer (D): 22,200 (derivative) · Disposition to issuer (D): 23,000 (derivative) · Disposition to issuer (D): 33,000 (derivative) | EDGAR |
| 2023-04-27 | 4 | CATLIN AVERY W — Director | Code (U): 10,000 · Code (U): 10,000 · Disposition to issuer (D): 128,981 (derivative) · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 22,200 (derivative) · Disposition to issuer (D): 23,000 (derivative) · +1 more | EDGAR |
| 2023-04-24 | 4 | Sessa Capital (Master), L.P. — 10% owner Sessa Capital GP, LLC — 10% owner Sessa Capital IM, L.P. — 10% owner Sessa Capital IM GP, LLC — 10% owner Petry John — 10% owner | Gift (G): 202,314 @ $0 · Gift (G): 224,617 @ $0 | EDGAR |
| 2023-04-18 | 4 | Sessa Capital (Master), L.P. — 10% owner Sessa Capital GP, LLC — 10% owner Sessa Capital IM, L.P. — 10% owner Sessa Capital IM GP, LLC — 10% owner Petry John — 10% owner | Option exercise/expiry (X): 8,879,023 @ $6 · Sale (S): 2,190,549 @ $24.32 · Option exercise/expiry (X): 8,879,023 (derivative) @ $0 | EDGAR |
| 2023-04-14 | 4 | Leon Francisco — Chief Scientific Officer | Gift (G): 1,500,000 @ $0 · Gift (G): 1,500,000 @ $0 | EDGAR |
| 2023-04-14 | 4 | CATLIN AVERY W — Director | Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 | EDGAR |
| 2023-04-04 | 4 | Sessa Capital (Master), L.P. — 10% owner Sessa Capital GP, LLC — 10% owner Sessa Capital IM, L.P. — 10% owner Sessa Capital IM GP, LLC — 10% owner Petry John — 10% owner | Other (J): 3,000,000 @ $0 · Gift (G): 218,651 @ $0 | EDGAR |
| 2023-02-14 | 4 | Leon Francisco — Chief Scientific Officer | Option exercise (M): 50,000 @ $2.50 · Sale (S): 50,000 @ $10.11 · Option exercise (M): 25,985 @ $2.50 · Sale (S): 25,985 @ $10.04 · Option exercise (M): 50,000 (derivative) @ $0 · Option exercise (M): 25,985 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Hoitt Jason — Chief Commercial Officer | Sale (S): 4,500 @ $10.00 | EDGAR |
| 2023-02-14 | 4 | Palmer Ashleigh — Director and CEO, Director | Option exercise (M): 50,000 @ $2.50 · Sale (S): 50,000 @ $10.11 · Option exercise (M): 25,835 @ $2.50 · Sale (S): 25,835 @ $10.04 · Option exercise (M): 50,000 (derivative) @ $0 · Option exercise (M): 25,835 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Leon Francisco — Chief Scientific Officer | Option exercise (M): 24,015 @ $2.50 · Sale (S): 24,015 @ $10.27 · Option exercise (M): 24,015 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Sessa Capital (Master), L.P. — 10% owner Sessa Capital GP, LLC — 10% owner Sessa Capital IM, L.P. — 10% owner Sessa Capital IM GP, LLC — 10% owner Petry John — 10% owner | Sale (S): 3,000,000 @ $9.40 | EDGAR |
| 2023-01-20 | 4 | Palmer Ashleigh — Director and CEO, Director | Option exercise (M): 24,165 @ $2.50 · Sale (S): 24,165 @ $10.27 · Option exercise (M): 24,165 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Palmer Ashleigh — Director and CEO, Director | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Yi Miyoko Christina — Chief Operations Officer | Grant/award (A): 21,000 (derivative) @ $0 · Grant/award (A): 187,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Osorio Benedict — Chief Quality Officer | Grant/award (A): 187,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | O'Brien Sarah — Chief People Officer | Grant/award (A): 8,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Leon Francisco — Chief Scientific Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | King-Jones Heidy — Chief Legal Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Hoitt Jason — Chief Commercial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Chauche Thierry — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Vogel Justin — Chief Accounting Officer | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Ramos Eleanor — Chief Medical Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Jain Rita — Director | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | Leon Francisco — Chief Scientific Officer | Option exercise (M): 187,000 @ $2.50 · Sale (S): 187,000 @ $10.26 · Option exercise (M): 187,000 (derivative) @ $0 | EDGAR |
| 2022-12-29 | 4 | Leon Francisco — Chief Scientific Officer | Option exercise (M): 10,674 @ $2.50 · Sale (S): 10,674 @ $10 · Option exercise (M): 10,674 (derivative) @ $0 | EDGAR |
| 2022-12-27 | 4 | Leon Francisco — Chief Scientific Officer | Option exercise (M): 1,568 @ $2.50 · Sale (S): 1,568 @ $10.00 · Option exercise (M): 375 @ $2.50 · Sale (S): 375 @ $10 · Option exercise (M): 1,568 (derivative) @ $0 · Option exercise (M): 375 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Osorio Benedict — Chief Quality Officer | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Leon Francisco — Chief Scientific Officer | Grant/award (A): 20,663 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Yi Miyoko Christina — Chief Operations Officer | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Hoitt Jason — Chief Commercial Officer | Grant/award (A): 120,000 (derivative) @ $0 · Grant/award (A): 20,663 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Palmer Ashleigh — Director and CEO, Director | Grant/award (A): 20,663 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Ramos Eleanor — Chief Medical Officer | Grant/award (A): 20,663 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Yi Miyoko Christina — Chief Operations Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | King-Jones Heidy — Chief Legal Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Leon Francisco — Chief Scientific Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Palmer Ashleigh — Director and CEO, Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Provention Bio, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-04-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-24 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-16 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-02-13 | 8-K | 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PRVB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs